NCT04536636View on ClinicalTrials.gov

Docohexanoic Acid in Hemodialysis Patients

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Chronic Renal Failure
Interventions
DRUG

Docohexanoic acid

Patients received 650 mg DHA/3 times/wk/post-HD session

DRUG

Control-No drug

Patients received usual medical care with no DHA

Trial Locations (1)

28034

Hospital Ramón y Cajal, Madrid

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

NCT04536636 - Docohexanoic Acid in Hemodialysis Patients | Biotech Hunter | Biotech Hunter